Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end.
Michael Siluk | UCG | Getty Images
For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She’d tried five different programs in her life and never found lasting results.
Her luck started to change last year, when she saw a promotion on Instagram for the Ro Body Program, a new offering from online health startup Ro. The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that’s turned into a booming business in recent years.
Beard, 47, had previously sought a GLP-1 prescription, but her doctor “wouldn’t even try” to get it approved, assuming her insurance company would reject coverage of the costly medication, she said. GLP-1s cost roughly $1,000 per month before insurance and other rebates.
Customers of Ro’s Body Program could get prescribed a GLP-1, such as Novo Nordisk ‘s weight loss drug Wegovy or diabetes treatment Ozempic, and meet monthly with a doctor. They also get access to an educational curriculum, 24/7 messaging, one-on-one coaching with nurses and assistance with navigating insurance complexities.
Beard was 210 pounds when she first started the program early last year. She’s since lost 40 pounds and serves as an ambassador for Ro. She pays $30 per month for the GLP-1 treatment, after insurance coverage, along with a $145 monthly fee for the program. And she has no plans to leave.
“I’m fine if I have to stay on it forever,” Beard told CNBC.
Ro, founded as Roman in 2017, is part of a growing crop of digital health companies aiming to capitalize on the soaring demand for GLP-1s by building programs and services for users on top of the medications. The opportunity could be massive. Goldman Sachs analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, and predict the industry could reach $100 billion in annual revenue by that time.
In addition to Wegovy and Ozempic, the GLP-1 class includes Eli Lilly’s highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. GLP-1s mimic a hormone produced in the gut to suppress a person’s appetite and regulate blood sugar.
Like Ro, other non-drugmakers, including Calibrate, Sesame, Omada Health, Noom, Hims & Hers and even telehealth industry veterans Teladoc Health and WeightWatchers, have rolled out offerings geared toward patients on GLP-1s, or have expanded their services to include the popular medications.
Meanwhile, investors are cheering them on.
Shares of Ro competitor Hims & Hers popped 28% on May 20 after the company said it’s now offering compounded GLP-1 injections in addition to its oral medication kits. CEO Andrew Dudum told CNBC the company is confident customers will be able to access a consistent supply of the injections.
Supply shortages are one of the big hurdles for companies in the market, as spiking demand has made it difficult for many patients to access the treatments. There’s also been a rise of counterfeit products, according to the World Health Organization, which said in January that the combination of shortages and the “increased circulation of falsified versions” is particularly problematic for patients with Type 2 diabetes who count on the medication for disease management.
That’s not slowing down industry executives like Ro founder Zachariah Reitano.
Ro didn’t start out as a company focused on weight loss. Reitano launched it to sell treatments online for erectile dysfunction before moving on to hair loss and other pathologies.
In 2020, Ro switched to obesity management and, after Wegovy was approved by the Food and Drug Adminstration the following year, Reitano said patient inquiries started pouring in by the “tens of thousands.”
Now, Ro is shoveling marketing dollars into its GLP-1 program — from digital ads, TV commercials and posters lining subway stations, to influencer campaigns featuring patients such as Beard.
Reitano told CNBC that GLP-1s are like a “jetpack for positive behavior change.” Patients tend to exercise more, eat healthier and see around a 30% reduction in calorie intake, he said.
“Once you get a little bit of momentum, once you lose a little bit of weight, you’re sleeping better, you have more energy, you can go to the gym, you can eat better and then that’s that positive flywheel,” Reitano said.
Ro has raised around $1 billion in funding to date, according to PitchBook. The company was valued at about $7 billion as of early 2022, though that was before a steep drop in tech stocks and collapse in the initial public offering market forced many startups to dramatically lower their valuations.
WeightWatchers joins the market
WeightWatchers has been in business for over 60 years and is the name in the U.S. perhaps most synonymous with weight loss programs.
In December, the company entered the GLP-1 market, with a behavioral-support program that’s available through its general membership subscription, starting at $23 per month. Members can participate whether they get a GLP-1 prescription through their primary care physician or through the new WeightWatchers Clinic, introduced alongside the behavioral program.
Because GLP-1s suppress appetites, WeightWatchers quickly learned that it needed an entirely new program for people taking the meds, said Gary Foster, the company’s chief scientific officer.
“They don’t need help with what to do for dessert or how to deal with the bread on the table at a restaurant,” Foster said in an interview. “That’s like 50-60% of what we would do for people without meds.”
Clinic members who participate in the GLP-1 program have to pay an additional fee — starting at $99 a month — for exclusive access to registered dieticians, fitness professionals and care team coordinators.
WeightWatchers said in its first-quarter results earlier this month that 87,000 people had subscribed to the clinic, although not all of them are taking GLP-1s. The company expects to have between 140,000 and 160,000 clinic subscribers by year-end, the report said.
It hasn’t been enough to change WeightWatchers’ trajectory. The stock has plummeted 83% this year on concerns about the company’s debt load, its core weight loss business and Oprah Winfrey’s announced departure from the board in February.
With respect to GLP-1s and their impact on weight loss, “the landscape is quite exciting,” Foster said. “I think we should all celebrate and really be delighted by the fact that there are more tools in the toolbox to help people trying to manage their weight.”
Kim Gradwell with an Ozempic injection needle at her home in Dudley, North Tyneside, Britain, October 31, 2023.
Lee Smith | Reuters
Jennifer VanGilder, a 51-year-old economics professor at Ursinus College in Collegeville, Pennsylvania, said she’d tried countless methods to lose weight, from strict diets to services like the defunct Jenny Craig. She was considering bariatric surgery before she came across a program from digital health startup Calibrate.
Calibrate, founded in 2019, was one of the first companies to treat obesity by combining GLP-1s with one-on-one coaching. The program costs $199 a month, which doesn’t include the medication, and requires an initial three-month-long commitment.
VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. She later switched to Wegovy.
VanGilder said GLP-1s aren’t a miracle drug, but by taking them and putting in the work, she said she lost around 100 pounds of her 242-pound weight. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn’t feel like she’s dieting.
“That’s why I’ve been able to stay on it for as long as I have,” VanGilder said.
Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The company’s 2024 report examined data from roughly 16,000 members who completed at least one year of the program as of October, along with a smaller group of patients who continued for longer.
Average weight loss among patients was 16.2% at 12 months in the program, 17.3% at 18 months and 17.9% at 24 months, according to the report.
“Our data of proven outcomes shows that we can deliver faster, better results than some of the leading GLP-1 clinical trials,” said Dr. Kristin Baier, Calibrate’s vice president of clinical development, in an interview.
But Calibrate has hit some major speed bumps in the past couple years.
After raising $100 million in venture funding during the peak of the tech market in 2021, the combination of supply shortages, insurance challenges and the broader market swoon forced the startup to lay off hundreds of employees between 2022 and 2023. The company was acquired in October at a discount by private equity firm Madryn Asset Management.
Calibrate CEO Rob MacNaughton said the sector was “ill equipped” to manage the “dramatic demand that led to, at some point, severely, severely constrained supply” of GLP-1s last year.
Under new ownership, the company continues to promote its GLP-1 service, which its said is important because the drugs themselves aren’t sufficient.
“GLP-1 medications, while they are safe and effective, they are a tool,” said Baier. “They are not the entire treatment.”
Options for patients
Ro’s Reitano said shortages of Wegovy and other GLP-1s last year prompted his company to temporarily pause advertising. Ro also dolled out refunds and credits to patients in its program who weren’t able to pick up their medication within 30 days of receiving a prescription, he said.
Reitano said Ro has built up “both technical tools and operations” to help patients navigate supply issues. That includes transferring prescriptions to different pharmacies based on their GLP-1 supply and proximity to a patient. From July to August, the company made 50,000 phone calls to pharmacies across the U.S. to coordinate those transfers, Reitano said.
Ro has also expanded its medication offerings, adding Zepbound following its U.S. approval in November.
“We added that to our formulary, and that’s really when we started advertising again because we had confidence that we’d be able to get patients an option,” Reitano said.
Insurance problems persist, though.
Some employers have dropped weight loss drugs from their plans due to the costs associated with covering the treatments for thousands of patients. The federal Medicare program by law can’t cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health.
Eli Lilly and Novo Nordisk offer commercial savings card programs that aim to expand access to their GLP-1s. Eli Lilly allows people with insurance coverage for Zepbound to pay as low as $25 for a monthly prescription. And users who can’t get insurance coverage, may be able to get the drug for as low as $550 a month.
The high costs and difficult access led Hims & Hers to initially stay out of the GLP-1 market even after launching its new weight loss program in December
Dr. Craig Primack, senior vice president of weight management at Hims, said the company decided to offer treatment regimens based on drugs that had been studied and prescribed for decades.
“We’re going to have people, for one reason or another, who either don’t want an injection at this point, or are just looking for a different alternative,” Primack told CNBC in an interview in March. “These are tools we’ve been using in our field for a long, long time.”
Last week, Hims said customers can now access compounded GLP-1 medications via a prescription from a licensed health-care provider on the platform. Hims said it plans to make branded GLP-1 medications available to its customers once supply is consistently available. The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.
Dudum said the company has partnered with one of the largest generic manufacturers in the U.S. and has a certain degree of exclusivity with the facility. The manufacturer has FDA oversight, he said.
Even before Hims introduced compounded GLP-1 injections to its weight loss offering, the company said it expects the program will generate more than $100 million in revenue by the end of 2025.
Beard, the Ro customer, has had to make some changes since starting the Body Program. She initially took Wegovy with no out-of-pocket costs, thanks to her insurance coverage and a savings card program from Novo Nordisk. But she hit a plateau on the drug, so she switched to Zepbound.
While there have been some hiccups along the way, Beard says the program has largely been a “seamless” addition to her day-to-day life, and that she no longer thinks about food all the time. She even got a family member to enroll.
“We’re not having any bad side effects, so why go off of it?” she said, adding “it’s helped both of us get to the weight we want.”
Nscale, the UK-headquartered AI infrastructure provider.
Courtesy: Nscale
Two years ago, Nscale was a brand new startup in the U.K. that had yet to raise any outside funding or officially announce its existence.
Last year the London-based company came out of stealth, and in December announced that it had raised its Series A fundraising, totaling $155 million.
Now, Nscale finds itself at the center of the action in the hottest market on the planet: artificial intelligence. And it has close to $700 million in fresh capital from Nvidia, the world’s most valuable company.
In press releases on Tuesday, Nscale was named as an AI infrastructure partner for Nvidia, Microsoft and OpenAI, as the companies expand their buildouts in the U.K. Nscale then said it signed a five-year $6.2 billion agreement with Microsoft and Aker to develop “hyperscale AI infrastructure” in Europe, specifically Norway, where Aker is headquartered.
OpenAI made prior headlines with Nscale, announcing plans in July for a data center in Norway for a Stargate-branded AI data center. Nscale agreed to commit $1 billion for the project, with the goal of racking up 100,000 Nvidia graphics processing units (GPUs) at the site before 2027.
It’s a remarkably quick rise for a company that wasn’t even around when OpenAI kicked off the generative AI boom with the launch of ChatGPT in late 2022. At that time, what’s now Nscale was part of Arkon Energy, which was established a year earlier to provide infrastructure for cryptocurrency mining. Nscale was spun out to address soaring demand for data centers capable of handling AI workloads.
Read more CNBC tech news
Like CoreWeave, which went public this year and now sports a market cap of $58 billion, Nscale is combining data center space, power and lots of GPUs with its own software in order to an provide end-to-end service for AI infrastructure.
CoreWeave, which supplies infrastructure to Microsoft, Google, Nvidia and OpenAI, also has roots in crypto. Founded in 2017, the company built up its initial fleet of Nvidia GPUs for ethereum mining before pivoting to AI.
Nscale didn’t respond to a request for comment following this week’s announcements, but CEO Josh Payne, who previously founded Arkon, told CNBC in late July that the company was targeting two big problems in Europe. One is a lack of sufficient computing capacity and the other is a “very fragmented market.”
“What the continent needs is large AI infrastructure projects deploying compute [power],” Payne said, after the announcement with OpenAI for the Norway buildout. “The ecosystem can consume from the project to build AI products, to generate productivity growth and economic benefit.”
Payne wrote in a LinkedIn post on Wednesday that the agreement with Microsoft and Aker is a “huge win for European-owned AI infrastructure.”
Europe has been pushing the concept of “sovereign AI,” requiring data centers and AI workloads to be located and processed on European soil. Nscale has quickly emerged as an important player in the U.K.’s bid to evolve into a global leader in AI. In January, Britain laid out an AI “action plan,” promising to reduce bureaucracy to help its domestic AI sector thrive.
While Nscale is addressing the European market, many of its early partners are big U.S. AI vendors. They timed their announcements on Tuesday to President Donald Trump’s state visit to the U.K.
On Wednesday, Trump visited Windsor Castle and met with King Charles, Queen Camilla and other members of the royal family. His trip comes at a contentious moment for U.K. Prime Minister Keir Starmer, who is under pressure to bring stability to the country after the exit of Deputy Prime Minister Angela Rayner over a house tax scandal and a major cabinet reshuffle.
Microsoft headlined the U.K. announcements, committing $15.5 billion of new investment to computing equipment. The software giant said it plans to work with Nscale to construct what will become the U.K.’s largest supercomputer in Loughton, a suburban town in the English county of Essex.
The site will initially house 23,040 Nvidia Blackwell GPUs to be delivered in the first quarter of 2027. When it goes live, it will generate 50 megawatts of AI capacity, scalable to 90 megawatts, according to a statement from Nscale.
“No one can make that kind of capital investment unless they’ve got somebody already committed to spend the money once the work is complete, and that’s the role we’re playing,” Microsoft President Brad Smithsaid Tuesday, adding the deal represents a major vote of confidence in Nscale.
OpenAI said it would launch a U.K. version of Stargate through a partnership with Nscale and Nvidia. OpenAI will deploy 8,000 GPUs in the project’s first phase early next year, with the option to expand capacity to approximately 31,000 GPUs over time.
Stargate U.K. will operate across a number of sites in the country — one of the early ones being Cobalt Park, an industrial state in the Northern English city Newcastle. Stargate was initially spawned in the U.S. in January as part of President Trump’s effort to push investments in AI infrastructure.
Nvidia CEO Jensen Huang attends the “Winning the AI Race” Summit in Washington D.C., U.S., July 23, 2025.
Kent Nishimura | Reuters
Nvidia’s announcement on Tuesday included an investment of up to £11 billion ($15 billion) with Nscale and CoreWeave to boost U.K. AI infrastructure.
Nvidia CEO Jensen Huang separately revealed on Wednesday that the chipmaker had made a £500 million ($683 million) equity investment into Nscale.
“We convinced ourselves that Nscale could be a national champion for AI infrastructure in the U.K.,” Huang told journalists at a press conference in London.
Nick Patience, AI practice lead at the Futurum Group, told CNBC that Nscale is “a key part of Nvidia’s push in the U.K. market and an acknowledgment by the government that it has to do something to get the AI infrastructure built here, which has been a long slog.”
Rapid growth
After exiting stealth in May of last year, Nscale’s first public announcement came two months later, when the company partnered with UAE’s Open Innovation AI to deploy 30,000 GPUs. Around the same time, Nscale said it was acquiring Kontena, which was founded in 2018 and specialized in high-performance computing data centers.
The next month, Nscale announced an agreement with Asian telecom company Singtel to offer a “GPU-as-a-Service (GPUaaS),” and serve customers in Europe and Southeast Asia. Initially, Nscale’s infrastructure relied on GPUs from Advanced Micro Devices. Today, the startup promotes various offerings from market leader Nvidia.
Nscale’s big financing landed in December, when the company said it raised $155 million in a round led by Sandton Capital Partners, with participation from Kestrel0x1, Blue Sky Capital Managers and Florence Capital.
Sandton co-founder Rael Nurick said in the press release that with its “unique vertically integrated approach, Nscale is building the hyperscale AI platform to power AI at scale.”
Nscale said at the time that it had grown its AI data center pipeline to 1.3 gigawatts from 300 megawatts the prior year to and that it was aiming to have 350,000 GPUs running by the end of 2027.
By comparison, CoreWeave said at a banking conference last week that its portfolio consists of “about 2.2 gigawatts of capacity that’s coming online.” The company said in its IPO prospectus in March that its 32 data centers were running 250,000 GPUs.
It’s been a whirlwind few years for Payne, Nscale’s founder. While he was serving as executive chairman of Arkon, he was also operating chief at Australia’s Battery Future Acquisition Corp., a blank check company that says it’s “targeting critical battery minerals and related supply chains.”
He’s got a lot of work in front of him.
Building out AI data centers with costly GPUs is a capital intensive process that’s historically required a hefty amount of debt. CoreWeave had raised a total of $12.4 billion in debt through the end of 2024, in addition to well over $1 billion in equity financing before its IPO. It announced a $1.5 billion bond sale in July after a $2 billion debt offering in May.
Nscale was trying to raise $1.8 billion earlier this year through a private credit deal led by bankers at Goldman Sachs, according to Bloomberg.
In the December video tied to Nscale’s equity fundraising, Payne called it “one of the largest Series As raised in U.K., European history.” He said the company would use the cash to deploy up to another 4,000 GPUs in its data center in Norway and to develop up to 180 megawatts of capacity in the company’s portfolio.
The aim, Payne said, was to deploy 50,000 GPUs by the end of 2025 and 150,000 by the end of next year.
“The key challenges that we see in the market is the significant increase in density at the GPU level,” he said. “This funding allows us to scale up materially” he said, and to become “one of the largest players in Europe.”
Eric Baker, co-founder and CEO of Ticket reseller StubHub, rings the opening bell during his company’s IPO at the New York Stock Exchange in New York City, U.S., September 17, 2025.
Brendan McDermid | Reuters
StubHub shares opened at $25.35in their New York Stock Exchange debut on Wednesday after the online ticket seller priced its IPO in the middle of its expected range.
The pricing late Tuesday at $23.50 per share raised $800 million for the company, now trading under ticker symbol “STUB.”
StubHub’s long-awaited IPO comes after the company paused its plans in April, when President Donald Trump’s “Liberation Day” tariffs sent the stock market into a tailspin. It was the second such delay, after market volatility forced StubHub to temporarily shelve its IPO plans in July 2024.
The IPO is the latest in a flurry of tech offerings as the market rebounds from a dismal few years. Swedish buy now, pay later firm Klarna and Gemini, the crypto firm founded by Cameron and Tyler Winklevoss, rose in their respective debuts last week. Peter Thiel-backed cryptocurrency exchangeBullish, design software company Figma and stablecoin issuer Circle have also hit the market in recent months.
StubHub has been through a number of transactions in its 25-year history to get to this point. It was purchased by eBay for $310 million in 2007, but was reacquired by its co-founder Eric Baker in 2020 for roughly $4 billion through his new company Viagogo.
Read more CNBC tech news
StubHub has benefited from a resurgence in the live events market in the years following the Covid lockdowns. Sales have also boomed from massively popular shows like Taylor Swift’s Eras Tour and Beyoncé’s Renaissance Tour, as well as sporting events like the Super Bowl.
The company said in its updated prospectus filed last month that those sorts of events can also make StubHub’s revenues lumpy and difficult to predict.
In the first quarter, StubHub reported revenue growth of 10% from a year earlier to $397.6 million. Its net loss widened to $35.9 million from $29.7 million a year ago. Gross merchandise sales, which represent the total dollar value paid by ticket buyers, reached $2.08 billion in the three months ended March 31.
StubHub primarily generates revenue from connecting buyers with ticket resellers. More than 40 million tickets were sold on StubHub’s marketplace last year from roughly one million sellers, the company said in August.
The Federal Trade Commission is in the advanced stages of probing Ticketmaster over whether it’s done enough to keep automated bots from circumventing its per-person ticket limits for popular events, Bloomberg reported Monday, citing people familiar with the matter.
The FTC in May sent a warning letter to StubHub saying it must comply with the agency’s “junk fees” rule and alleging some of its ticket listings failed to display the total price, including all mandatory fees and charges.
Madrone Partners is StubHub’s largest investor with ownership of 24.5% of Class A shares prior to the offering. WestCap is second at 12.3%, followed by Bessemer Venture Partners at 8.8%.
It’s been a decade since Kayvon Beykpour sold Periscope to Twitter for a reported $100 million, allowing the social media site to jump into livestreaming.
Twitter shuttered Periscope in 2021, and the parent company, now called X and owned by Elon Musk, gravitated to a live events product called Spaces.
Meanwhile, Beykpour, who spent seven years at Twitter after the acquisition, is back with Macroscope. He said on Wednesday that he’s raised $40 million from venture investors, including GV (formerly Google Ventures), Lightspeed Venture Partners and Thrive Capital.
While Periscope targeted a consumer audience, Macroscope is going squarely after businesses. Beykpour’s idea is to help software developers easily spot issues in their code, and show managers what their engineers are doing.
Beykpour said the lack of transparency in the software development process was a big problem in his former gig.
“So much of my job as the head of product at Twitter was just understanding what the hell was happening,” Beykpour, said in an interview. “You have all these engineers at the company and all these very important things that we need to get done with absolute opaqueness around, like, What progress did we make? What are all these people working on?”
He said the startup set out to help product leaders first and added features for programmers later.
Macroscope integrates with Microsoft-owned GitHub’s source code repositories and project management software from Atlassian and Linear. Its technology connects to artificial intelligence models from Anthropic, Google and OpenAI that can propose alternative code and answer questions from developers and product executives.
Products like GitHub Copilot and Cursor’s BugBot already can review code with help from AI. Beykpour said that in testing Macroscope outperformed competitors when it came to correctly identifying known software bugs.
And when it comes to tools to help managers stay on top of developers’ activity, there’s not much available, Beykpour said.
“They’re solving it with meetings,” he said. “If we cannot surpass the bar of, people call a meeting to ask a bunch of engineers what’s happening, we’ve failed miserably.”
Macroscope costs $30 per developer per month, which includes the status-checking components for bosses, while Cursor is priced at $32 per month when purchased annually.
Early users include film studio A24, online learning startup Class and probiotics company Seed Health.
Beykpour started Macroscope in 2023 with Periscope co-founder Joseph Bernstein and Rob Bishop, founder of AI startup Magic Pony, which Twitter acquired in 2016. The company has 17 employees and is based in San Francisco.